Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 22, 2014
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)Lin Shen, Jin Li, Jianming Xu, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2015
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancerJinwan Wang, Ruihua Xu, Jian Li, et al.International Journal of Surgery (London, England)|April 10, 2024
Thermal ablation with and without adjuvant systemic therapy: a nationwide multicenter observational cohort study of solitary colorectal liver metastasesJianming Li, Chuan Pang, Guangjian Liu, et al.BMC Medicine|January 16, 2026
Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion studyXiaoyu Li, Ruihong Dai, Qi Xu, et al.British Journal of Cancer|May 2, 2022
MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2Weiwei Yan, Qiuying Han, Lin Gong, et al.Radiology|June 30, 2026
Sequencing Ablation and Systemic Therapy in Colorectal Liver Oligometastases: An Upfront versus Delayed Approach Nationwide AnalysisJianming Li, Chuan Pang, Huarong Li, et al.Ebiomedicine|January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyLin Yang, Wen Zhang, Nanfeng Fan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2018
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients WithShukui Qin, Jin Li, Liwei Wang, et al.Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.Nature Communications|February 15, 2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)Jianming Xu, Yi Li, Qingxia Fan, et al.Pageof 11